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Background: Elevated white blood cell count (WBC) is associated with increased major adverse 
cardiovascular events (MACE) in the setting of acute coronary syndrome (ACS). The aim of this 
study was to evaluate whether similar associations persist in an all-comers population of patients 
undergoing percutaneous coronary intervention (PCI) in the contemporary era. 
Methods and Results: In the multicenter prospective observational patterns of non-adherence to 
anti-platelet regimens in stented patients (PARIS) study, 4222 patients who underwent PCI in the 
USA and Europe between July 1, 2009 and December 2, 2010 were evaluated. The association 
between baseline WBC and MACE (composite of cardiac death, stent thrombosis, spontaneous 
myocardial infarction, or target lesion revascularization) at 24 months follow-up were analyzed 
using multivariable Cox regression. Patients with higher WBC were more often younger, 
smokers, and with less comorbid risk factors compared to those with lower WBC. After 
adjustment for baseline and procedural characteristics, WBC remained independently associated 
with MACE (hazard ratio (HR) per 103 cells/uL increase 1.05 [95% confidence intervals (CI) 
1.02-1.09], p=0.001), cardiac death (HR 1.10 [1.05-1.17], p<0.001, and clinically indicated 
target revascularization (HR 1.04 [1.00-1.09], p=0.03), but not stent thrombosis (HR 1.07 [0.99-
1.16], p=0.10) or spontaneous myocardial infarction (HR 1.03 [0.97-1.09] p=0.29). The 
association between WBC and MACE was consistent in ACS and non-ACS presentations 
(interaction p=0.15). 
Conclusions: Increased WBC is an independent predictor of MACE after PCI in a contemporary 
all-comer cohort. Further studies to delineate the underlying pathophysiologic role of elevated 
WBC across a spectrum of coronary artery disease presentations are warranted.  
Keywords: white blood cell, major adverse cardiovascular events, percutaneous intervention
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 Introduction 
Inflammation is increasingly recognized as a key player in the development of major adverse 
cardiovascular events (MACE) (1-2). In addition, much has been hypothesized about the role of 
inflammation on the initiation and propagation of atherothrombosis, and current data highlight 
the importance of the inflammatory thrombosis interface (3-4). White blood cell count (WBC) is 
considered a marker of inflammation measured on routine hemograms, and earlier studies 
demonstrated an association between WBC and MACE in patients with acute coronary syndrome 
(ACS) (5-6). However, as medical therapy has evolved, a greater proportion of patients are on 
dual antiplatelet and statin therapies, which have been shown to attenuate systemic inflammatory 
markers and the inflammatory-thrombosis interface (7-10). Although recent data do demonstrate 
a persistent association between WBC and MACE in contemporary patients with ACS 
undergoing percutaneous coronary intervention (PCI), whether or not this association is present 
in a contemporary all-comers population undergoing PCI remains uncertain (11).  
 
In this analysis of the multicenter, international, prospective, observational patterns of non-
adherence to anti-platelet regimens in stented patients (PARIS) study with adjudicated clinical 
events, we sought to determine the association between WBC and MACE in an all-comers 
population in the current era of optimal medical therapy and PCI technique. 
  
Methods 
Study design and cohort 
The prospective observational PARIS registry was designed to evaluate different dual anti-
platelet therapy cessation methods and cardiovascular risk after PCI. Details of the registry have 
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been previously described (12). Of the 5031 patients who underwent successful PCI and were 
enrolled in the PARIS registry from 15 sites across the United States and Europe between July 1, 
2009 and December 2, 2010, 809 (16%) were excluded due to missing WBC. A total of 4222 
(84%) patients comprised the currently studied final cohort. Participation in the registry was 
voluntary and requires written informed consent.  
 
The PARIS registry was funded in part by Bristol-Myers Squibb and Sanofi-Aventis; however, 
the funding agencies had no role in the design, collection, analysis, or interpretation of the data, 
in the writing of this manuscript, or in the decision to submit this manuscript for publication. 
This study is registered with ClinicalTrials.gov, number NCT00998127.  
 
Variables of interest 
Baseline demographic characteristics and medical co-morbidities were self-reported, while body 
mass index was measured by clinical personnel at each site. The definitions of dyslipidemia, 
hypertension, and diabetes mellitus required the use of lipid-lowering, anti-hypertensive, and 
glucose-lowering agents, respectively. Prior coronary artery disease was defined as prior PCI, 
coronary artery bypass graft surgery, or myocardial infarction (MI). Tobacco use was defined as 
use within 30 days. Aspirin and thienopyridine use is defined as use on admission. 
 
Baseline WBC was measured at the time of the PCI by site-specific clinical laboratories. Tertiles 
of WBC were defined as follows: 1st tertile 2.1-7.1 x 103 cells/uL (n=1469), 2nd tertile 7.11-9.1 x 
103 cells/uL (n=1353), and 3rd tertile 9.11-29.0 x 103 cells/uL (n=1400). 
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Outcomes 
The primary outcome of interest was MACE defined as a composite of cardiac death, definite or 
probable stent thrombosis, spontaneous MI, or target lesion revascularization at 24-month 
follow-up. Secondary outcomes of interest included individual components of MACE. Definite 
and probable stent thrombosis were defined according to the academic research consortium 
criteria, and spontaneous MI was defined according the Universal Definition (13-14). Clinically 
indicated target lesion revascularization was defined as any repeat percutaneous intervention of 
the index lesion (within 5 mm of the previously placed stent) or surgical bypass of the index 
vessel. All outcomes were site reported and adjudicated by an independent clinical events 
committee. 
 
Statistical analyses 
Continuous variables are presented as mean + standard deviation, and categorical variables are 
presented as proportions. Co-variates and outcomes were compared across WBC tertiles using a 
test of trend. MACE over 24 months follow-up were compared across WBC tertiles using the 
Kaplan-Meier method. The unadjusted and adjusted associations between a per 103 cells/uL 
increase in WBC and outcomes were determined using a multivariable Cox regression model and 
presented as hazard ratio (HR) [95% confidence interval (CI)]. The following variables were 
included in the adjusted models: age, sex, body mass index, dyslipidemia, hypertension, diabetes 
mellitus, prior coronary artery disease, tobacco use, admission aspirin use, admission 
thienopyridine use, Gp IIb/IIIa use, ACS presentation, presence of thrombotic lesion, stent type, 
and stent length. The adjusted model also included mode of dual antiplatelet therapy cessation 
(recommended discontinuation, interruption, disruption), which was introduced as a time 
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dependent covariate as previously described (12). All statistical analyses were performed using 
STATA version 11.2 (StataCorp LP, College Station, Texas). All p-values are two-sided, with 
p<0.05 considered statistically significant.  
 
Results 
Baseline characteristics 
Baseline clinical and procedural characteristics across baseline WBC tertiles are shown in Tables 
1 and 2. Overall, a higher baseline WBC count was noted in younger patients with a lower 
proportion of medical comorbidities such as dyslipidemia, hypertension, diabetes mellitus, and 
prior coronary artery disease, but a higher proportion of tobacco use. Consistent with the lower 
rate of coronary artery disease, aspirin or thienopyridine use on admission was less frequent in 
patients with a higher baseline WBC count. Finally, patients with a higher baseline WBC count 
were more likely to present with an ACS, have a thrombotic lesion, and to be treated with Gp 
IIb/IIIa inhibitors and long bare metal stents. 
 
The proportion of patients with any dual antiplatelet therapy cessation was not significantly 
different across baseline WBC tertiles at 30 days (tertile 1: 3.2% [95% confidence interval 2.4-
4.3], tertile 2: 3.3% [2.4-4.4], tertile 3: 3.8% [2.9-5.0]; p=0.39) or 12 months (tertile 1: 23.2% 
[21.1-25.5], tertile 2: 24.6% [22.3-27.0], tertile 3: 25.0% [22.8-27.4]; p=0.33). However, at 24 
months there was a significant increase in any dual antiplatelet therapy cessation with increasing 
baseline WBC tertiles (tertile 1: 55.1% [52.5-57.8], tertile 2: 54.8% [52.1-57.6], tertile 3: 59.7% 
[57.1-62.4]; p=0.02). 
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Outcomes 
Outcomes stratified by baseline WBC tertiles are shown in Table 3 and Figure 1. The proportion 
of patients with the primary composite outcome of MACE was significantly higher in patients 
with a higher baseline WBC count at 30 days, 12 months, and 24 months follow-up, as were the 
individual components of cardiac death, definite/probable stent thrombosis, and clinically 
indicated target vessel revascularization. The proportion of patients with spontaneous MI, 
however, was not significantly different across baseline WBC tertiles. Results were consistent 
when outcomes were stratified by baseline WBC quartiles (Supplemental Table, Supplemental 
Figure). 
 
Unadjusted and adjusted associations between a per 103 cells/uL increase in WBC and and 
outcomes at 24-month follow-up are shown in Table 4. After adjustment for age, sex, body mass 
index, dyslipidemia, hypertension, diabetes mellitus, prior coronary artery disease, tobacco use, 
admission aspirin use, admission thienopyridine use, Gp IIb/IIIa use, ACS presentation, presence 
of thrombotic lesion, stent type, stent length, and mode of dual antiplatelet therapy cessation, 
there remained a significant association between WBC and MACE, cardiac death, and clinically 
indicated target lesion revascularization, but not definite or probable stent thrombosis or 
spontaneous MI. The association between WBC and MACE was consistent in ACS and non-
ACS presentations (interaction p=0.15). 
 
Other factors associated with an increase in long-term MACE were presence of diabetes mellitus, 
prior coronary artery disease, total stent length of >40 mm, and disruption of dual antiplatelet 
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therapy, while use of drug-eluting stent and recommended discontinuation of dual antiplatelet 
therapy was associated with lower long-term MACE. 
 
Discussion 
This large, prospective, multicenter, international, registry demonstrated a significant 
independent association between baseline WBC and independently adjudicated long-term 
MACE in an all-comers population of patients undergoing PCI. This association is independent 
of the presence of ACS, thereby raising a potential role for inflammation on clinical outcomes in 
patients across a spectrum of coronary artery disease presentations even in the current era of 
medical and device therapy. The significant independent association between baseline WBC and 
target lesion revascularization highlights the need to explore a potential role of inflammation 
and/or the inflammatory/thrombosis interface in the setting of PCI. Whether or not these 
associations would be attenuated with targeted anti-inflammatory therapy, however, remains 
uncertain.  
 
Earlier reports demonstrated an association between WBC and short-term outcomes in patients 
presenting with ACS. A substudy of the Thrombolysis in Myocardial Infarction (TIMI) 10A and 
10B trials evaluated 975 patients who underwent thrombolytic therapy for ST-segment elevation 
MI (5). A higher WBC count was noted in patients with a closed infarct artery and worse TIMI 
myocardial perfusion grades, which translated to a higher rate of 30-day mortality, new 
congestive heart failure, or shock. Another analysis from the 2208 patients in the Treat Angina 
with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy 
(TACTICS)-TIMI 18 study also demonstrated a significant association between higher WBC 
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counts and lower TIMI flow grades, lower perfusion grades, and higher rate of 6-month mortality 
(6).  
 
Medical therapy, however, has evolved significantly since these previous reports and current data 
support the anti-inflammatory effects of dual antiplatelet and statin therapy. Platelet P2Y12 
receptor inhibitors have been shown to significantly reduce the formation of aggregates between 
platelets and WBC subtypes, as well as cytokine release, in both experimental human models and 
patients with ACS (7-8). These platelet-WBC aggregates have been shown to be elevated across 
the spectrum of cardiovascular disease and associated with adverse cardiovascular outcomes (15-
18). Statin therapy has also been shown to significantly lower platelet-WBC aggregates and 
cellular adhesion molecules associated with the endothelial inflammatory response in the setting 
of ACS and stable coronary artery disease (9-10). These reductions parallel the significant 
reductions in MACE observed in patients on high dose statin therapy-undergoing PCI (19-21). In 
the current analysis, the patients with higher baseline WBC were younger and with less co-
morbidities, but with a significantly higher rate of tobacco use. Data on the impact of tobacco use 
on long-term outcomes has been mixed. Smokers have been shown to have lower mortality after 
an acute MI, termed the “smoker’s paradox”, and possibly due to their younger age and fewer 
co-morbidities (22). However, a recent study of the Global Registry of Acute Coronary Events 
further stratified by the type of acute MI presentations and demonstrated that over the years from 
1999 to 2007, smokers presenting with ST-segment elevation MI did not have a reduction in 30-
day mortality, while those with non-ST-segment ACS did demonstrate this reduction. 
Nonetheless, the association between baseline WBC in the current analysis remains independent 
of age, co-morbidities, ACS presentation, and tobacco use (23). 
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Device technology has also advanced over time to potentially decrease the inflammatory milieu 
induced by mechanical injury during PCI. Inflammatory responses to drug-eluting stent polymers 
were thought to play a large role in the underlying pathophysiology of in-stent restenosis and 
stent thrombosis. In earlier pre-clinical models, leukocytes were seen to be recruited soon after 
vascular injury. Rogers et al demonstrated that an antibody to the WBC adhesion integrin, Mac-1 
(CD11/CD18), led to a significant decrease in neointimal growth at the site of balloon 
denudation and stent-induced injury in animal models (24). Similar results were seen in rodent 
models that lacked the Mac-1 gene (25). In the bare metal stent era, a significant increase in 
CD11b and CD18 after PCI correlated with subsequent restenosis, while a single nucleotide 
polymorphism in the CD18 gene was shown to be associated with a significantly lower rate of 
restenosis at 1-year follow-up (26-27). Second generation drug-eluting stents were designed to 
reduce the inflammatory response with thinner strut designs and more biocompatible polymers, 
resulting in significantly lower rates of stent-related adverse events compared with earlier 
generation stents (28). In the current analysis, there was a significantly greater rate of thrombotic 
lesions with higher WBC tertiles. However, WBC remained an independent predictor of MACE 
and clinically indicated target lesion revascularization even after adjustment for presence of 
thrombotic lesion, anti-platelet therapy use, stent type, and stent length. 
 
The significance of an elevated WBC in ACS remains despite the improvements in medical 
therapy. A single-center retrospective observational study of 2833 patients presenting with ACS 
between December 1998 and October 2004 demonstrated a significant association between WBC 
subtypes and in-hospital and 6-month mortality (29). An analysis of 363 patients randomized in 
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the Evaluation of MCC-135 for Left Ventricular Salvage in Acute Myocardial Infarction 
(EVOLVE) study between May 2003 and November 2004 demonstrated that higher WBC and 
WBC subtypes independently predicted larger myocardial infarct size, lower left ventricular 
ejection fraction, and a higher rate of adverse clinical events in patients presenting with ST-
segment elevation MI and undergoing PCI (30). Although the clinical outcome was a not 
traditionally used composite of death, reinfarction, new or worsening congestive heart failure 
during index rehospitalization, all cardiac rehospitalizations, life-threatening ventricular 
arrhythmias, and new cardiogenic shock, the outcomes were adjudicated by an independent 
clinical events committee. In the Acute Catheterization and Urgent Intervention Triage Strategy 
(ACUITY) trial, WBC was an independent predictor of 1-year mortality in the 13,678 patients 
with moderate- or high-risk non-ST-segment elevation MI undergoing PCI between August 2003 
and December 2005 (31). More recently, WBC was associated with increased 1-year mortality in 
3193 patients who underwent PCI for ST-segment elevation MI between March 2005 and May 
2007 in the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial 
Infarction (HORIZONS-AMI) trial (11). 
 
In the setting of ACS, it remains uncertain if an elevated WBC is a marker of inflammation or a 
result of demargination in the setting of acute stress. The proposed pathophysiology of elevated 
WBC in the setting of stable coronary artery disease is even less clear. Very little data exists 
regarding a relationship of WBC and MACE in an all-comers population. One large multicenter 
prospective cohort study of 72,242 post-menopausal women enrolled in the Women’s Health 
Initiative Observational Study reported WBC to be an independent predictor of cardiovascular 
events, defined as fatal coronary heart disease, nonfatal MI, stroke and total mortality (32). The 
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multicenter, randomized A Coronary disease Trial Investigating Outcome with Nifedipine 
gastrointestinal therapeutic system (ACTION) trial also demonstrated a significant association 
between WBC and the composite of long-term death, MI, or stroke in 7311 patients with stable 
angina (33). However, both of these studies were conducted more than a decade ago, prior to the 
contemporary era of optimal medical therapy. More recently, a single-center registry of 3005 
consecutive patients referred for coronary angiography in Israel demonstrated a higher rate of 
MACE over a mean follow-up period of 486 days in patients with elevated neutrophil 
lymphocyte ratio (34).   
 
Despite the improvement in mortality related to coronary artery disease, there remains room for 
improvement, and an anti-inflammatory agent in addition to the current treatment algorithms 
may provide additional benefit in this patient population. A recent study by Nidorf et al 
demonstrated a significant reduction on the primary composite outcome of ACS, out-of-hospital 
cardiac arrest, or non-cardioembolic ischemic stroke in patients with stable coronary artery 
disease on anti-platelet and statin therapy randomized to receive the anti-inflammatory agent 
colchicine versus no colchicine (35). This is likely due to the effect of colchicine on the 
endothelial inflammatory response, as well as the inflammatory-thrombosis axis (36-37). Our 
results combined with previously published data lend support to ongoing studies targeting the 
inflammatory pathway across the spectrum of cardiovascular disease (NCT01594333, 
NCT02594111, NCT02551094).  
 
Limitations 
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There are several limitations to the current study. First, this secondary analysis of the PARIS 
registry was not pre-specified, and no causal relationships may be inferred from the associations 
observed in this prospective registry. Second, data on race, the use of statin therapy, and data on 
case urgency (with the exception of ACS presentation), such as left ventricular ejection fraction 
and presence of cardiogenic shock, were not collected. Third, 16% of the study population were 
excluded due to lack of WBC data and may represent a potential source of selection bias. 
Nonetheless, this remains the most current observation regarding the association between 
baseline inflammatory status and adjudicated clinical outcomes in a large, multicenter, 
international, prospective all-comers population. 
 
Conclusions 
Baseline WBC independently predicts MACE in a contemporary all-comers population 
undergoing PCI. In the setting of ACS, elevated WBC may represent a marker of inflammation 
or result from demargination in the setting of acute stress. Studies to determine the underlying 
pathophysiological role of elevated WBC in the setting of stable coronary artery disease are 
warranted. Trials evaluating the role of anti-inflammatory therapy in coronary artery disease are 
on-going. 
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Figure 1. Kaplan-Meier Curves of Major Adverse Cardiovascular Events Through 24 Months 
Stratified by Tertiles of Baseline White Blood Cell Count  
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Table 1. Baseline characteristics of patients discharged on dual anti-platelet therapy after 
percutaneous coronary intervention compared across baseline white blood cell count (WBC) 
tertiles  
 WBC  
tertile 1 
(2.1-7.1  
x 103 cells/uL) 
(n=1469) 
WBC  
tertile 2 
 (7.11-9.1  
x 103 cells/uL) 
 (n=1353) 
WBC  
tertile 3 
 (9.11-29.0  
x 103 cells/uL) 
 (n=1400) 
ptrend 
Age (years) 65.4 ± 10.6 64.1 + 11.0 61.8 ± 11.9 <0.001 
Male sex (%) 73.8 74.4 75.6 0.28 
Body mass index (kg/m2) 29.0 + 5.4 29.6 + 5.7 29.2 + 5.9 0.27 
Medical history (%)     
  Dyslipidemia 80.0 78.1 68.1 <0.001 
  Hypertension 84.8 81.7 75.1 <0.001 
  Diabetes mellitus 35.3 34.7 30.6 0.01 
  Prior coronary artery disease    
  (MI, PCI or CABG) 
54.7 49.8 38.8 <0.001 
  Stroke 3.2 3.3 3.3 0.90 
  Peripheral vascular disease 6.5 7.2 7.5 0.28 
Tobacco use (%) 11.4 17.7 31.0 <0.001 
Medications (%)     
  Aspirin 78.4 73.5 58.6 <0.001 
  Thienopyridine 50.6 41.9 32.0 <0.001 
  Gp IIb/IIIa inhibitor use 11.1 14.5 19.9 <0.001 
Cardiac status at admission (%)     
  Acute coronary syndrome 32.6 38.7 56.9 <0.001 
 
CABG = coronary artery bypass graft, Gp = glycoprotein, MI = myocardial infarction, PCI = 
percutaneous coronary intervention with stent placement 
Continuous data presented as mean + standard deviation 
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Table 2. Procedural characteristics of patients discharged on dual anti-platelet therapy after 
percutaneous coronary intervention compared across baseline white blood cell count (WBC) 
tertiles 
 
 WBC  
tertile 1 
(2.1-7.1  
x 103 cells/uL) 
(n=1469) 
WBC  
tertile 2 
 (7.11-9.1  
x 103 cells/uL) 
 (n=1353) 
WBC  
tertile 3 
 (9.11-29.0  
x 103 cells/uL) 
 (n=1400) 
ptrend 
Coronary artery treated (%)     
  Left main 2.9 2.7 2.8 0.90 
  Left anterior descending 46.6 47.5 44.4 0.26 
  Circumflex 30.4 30.9 30.6 0.93 
  Right coronary artery 33.6 32.2 37.6 0.03 
Number of arteries treated (%)     
  One 87.3 87.6 85.2 0.09 
  Two 11.9 11.6 14.2 0.07 
  Three 0.8 0.8 0.6 0.58 
Bifurcation lesion (%) 11.0 12.1 11.2 0.82 
Chronic total occlusion (%) 2.7 3.7 4.0 0.048 
Thrombotic lesion (%) 3.9 6.7 17.1 <0.001 
Stent type (%)     
  Bare metal  13.6 14.4 22.6 <0.001 
  1st generation drug-eluting stent 17.0 12.1 10.4 <0.001 
  2nd generation drug-eluting stent 69.4 73.5 66.9 0.16 
Total stent length (%)     
  <20 mm 41.5 35.5 32.6 <0.001 
  20 mm – 39 mm 35.1 36.7 35.5 0.83 
  >40 mm 23.4 27.9 31.9 <0.001 
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Table 3.  Outcomes of patients discharged on dual anti-platelet therapy after percutaneous coronary intervention compared across 
baseline white blood cell count (WBC) tertiles 
  WBC  
tertile 1 
(2.1-7.1 x  
103 cells/uL) 
(n=1469) 
WBC  
tertile 2 
 (7.11-9.1 x 
103 cells/uL) 
 (n=1353) 
WBC  
tertile 3 
 (9.11-29.0 x 
103 cells/uL) 
 (n=1400) 
ptrend 
Major adverse cardiovascular event 
(composite of cardiac death, definite or 
probable stent thrombosis, spontaneous 
myocardial infarction, or target lesion 
revascularization) (%) 
30 days 0.4 [0.2-0.9] 0.5 [0.3-1.1] 2.1 [1.5-3.0] <0.0001 
12 months 6.2 [5.1-7.6] 6.7 [5.5-8.2] 9.7 [8.3-11.4] 0.0002 
24 months 10.0 [8.6-11.7] 11.2 [9.6-13.0] 14.1 [12.4-16.1] 0.0004 
      
Cardiac death (%) 
30 days 0.1 [0.0-0.5] 0.2 [0.1-0.7] 0.6 [0.3-1.1] 0.01 
12 months 1.3 [0.8-2.0] 1.8 [1.2-2.7] 2.4 [1.7-3.4] 0.02 
24 months 2.4 [1.7-3.3] 3.6 [2.7-4.7] 3.9 [3.0-5.1] 0.02 
      
Definite/probable stent thrombosis (%) 
30 days 0.1 [0.0-0.6] 0.4 [0.2-1.0] 1.1 [0.7-1.8] 0.0007 
12 months 0.7 [0.4-1.3] 0.8 [0.5-1.5] 1.9 [1.3-2.8] 0.003 
24 months 0.9 [0.5-1.6] 1.3 [0.8-2.1] 2.3 [1.6-3.2] 0.003 
      
Spontaneous myocardial infarction (%) 
30 days 0.3 [0.1-0.8] 0.3 [0.1-0.8] 0.7 [0.4-1.3] 0.14 
12 months 2.1 [1.5-3.0] 1.7 [1.1-2.5] 2.8 [2.0-3.8] 0.20 
24 months 3.4 [2.5-4.5] 3.3 [2.4-4.4] 4.6 [3.6-5.9] 0.09 
      
Clinically indicated target lesion 
revascularization (%) 
30 days 0  0.4 [0.2-0.9] 1.2 [0.8-2.0] <0.0001 
12 months 3.9 [3.0-5.0] 4.6 [3.6-5.9] 7.0 [5.8-8.5] 0.0001 
24 months 6.2 [5.0-7.6] 7.0 [5.7-8.5] 9.4 [7.9-11.1] 0.0009 
 
Data are shown as crude estimates [95% confidence intervals]
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Table 4. Unadjusted and adjusted associations between a per 103 cells/uL increase in baseline 
white blood cell count and clinical outcomes at 24-month follow-up in patients discharged on 
dual anti-platelet therapy after percutaneous coronary intervention 
 Unadjusted Model 
 
Adjusted Model 
 Hazard Ratio 
(95% CI) 
p-
value 
Hazard Ratio 
(95% CI) 
p-
value 
Major adverse cardiovascular event  1.06 (1.03-1.09) <0.001 1.05 (1.02-1.09) 0.001 
Cardiac death  1.09 (1.03-1.15) 0.001 1.10 (1.05-1.17) <0.001 
Definite/probable stent thrombosis 1.14 (1.06-1.22) <0.001 1.06 (0.98-1.15) 0.12 
Spontaneous myocardial infarction  1.06 (1.00-1.11) 0.04 1.03 (0.97-1.09) 0.35 
Clinically indicated target lesion 
revascularization  
1.06 (1.02-1.10) 0.002 1.04 (1.00-1.09) 0.03 
 
Model adjusts for the following variables: age, sex, body mass index, dyslipidemia, 
hypertension, diabetes mellitus, prior coronary artery disease, tobacco use, admission aspirin use, 
admission thienopyridine use, glycoprotein IIb/IIIa use, acute coronary syndrome presentation, 
presence of thrombotic lesion, stent type, stent length, and mode of dual antiplatelet therapy 
cessation.   
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Figure 1.  
 
